TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14757967

Group type: EXPERIMENTAL
Intervention: 200 microg sodium selenite (Se-Se)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Stopped taking selenium (Se-0)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo followed by 200 microg sodium selenite (Plac-Se)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo without selenium substitution (Plac-0)
Number of subjects: 47
Study: 10830647

Group type: EXPERIMENTAL
Intervention: Cumulative incidence
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: Increment and incidence density measures
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: Crude DFS values
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: Adjusted DFS
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: Measurement of caries initiation and progression
Number of subjects: 2437
Study: 11990103

Group type: EXPERIMENTAL
Intervention: Chest harness
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sit harness
Number of subjects: 6
Study: 1626175

Group type: EXPERIMENTAL
Intervention: Doppler velocimetry with an index above 0.54 for induction of childbirth in 52 pregnancies
Number of subjects: 187

Group type: COMPARATOR
Intervention: Conventional monitoring methods in 132 cases
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Monitoring of fetuses beyond term by umbilical artery velocimetry
Number of subjects: 187
Study: 6373156

Group type: COMPARATOR
Intervention: Glaucine syrup 30 mg 3-times daily for 7 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Codeine syrup 30 mg 3-times daily for 7 days
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Glaucine capsules 30 mg 3-times daily for 28 days
Number of subjects: 130
Study: 31281005

Group type: EXPERIMENTAL
Intervention: Simulation-based exercise programme (aerobic and resistance exercise for a minimum of 25min per day, three times a week for 10 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 52
Study: 29753693

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) 600 mg and sodium ferrous citrate (SFC) 942 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-aminolevulinic acid (ALA) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium ferrous citrate (SFC) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALA+SFC
Number of subjects: 0
Study: 27694586

Group type: EXPERIMENTAL
Intervention: Refobacin bone cement R
Number of subjects: 62

Group type: COMPARATOR
Intervention: Palacos R + G
Number of subjects: 62
Study: 24710342

Group type: EXPERIMENTAL
Intervention: Corticosteroids treatment within 24 hours after admission
Number of subjects: 106
Study: 22305244

Group type: EXPERIMENTAL
Intervention: OMT+PR (Group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PR (Group 1)
Number of subjects: 20
Study: 20105415

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 18725648

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 15953803

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S‐Adenosylmethionine (SAMe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 12881343

Group type: EXPERIMENTAL
Intervention: Partial Tenon's capsule resection with adjunctive mitomycin C (MMC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Ahmed glaucoma valve implant without PTCR (control group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Both groups (PTCR with MMC and control)
Number of subjects: 92
Study: 10966009

Group type: EXPERIMENTAL
Intervention: Abciximab treatment during coronary artery bypass grafting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of EPILOG and EPISTENT studies
Number of subjects: 0
Study: 8937234

Group type: EXPERIMENTAL
Intervention: Small balloon catheter
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal balloon (Robinson's catheter with two condoms)
Number of subjects: 46
Study: 1567745

Group type: EXPERIMENTAL
Intervention: Saline solution (S-I)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Golytely solution (S-II)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Digestive irrigation with antibiotics
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Erythromycin and neomycin base
Number of subjects: 124
Study: 2865218

Group type: EXPERIMENTAL
Intervention: Bopindolol 1 mg (BP1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bopindolol 2 mg (BP2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lorazepam 2.5 mg (LR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Butalbital 75 mg (BT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bopindolol (BP1 and BP2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Butalbital (BT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lorazepam (LR)
Number of subjects: 100
Study: 31623958

Group type: EXPERIMENTAL
Intervention: Flexibility intervention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Strength intervention
Number of subjects: 40
Study: 30352399

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 28033302

Group type: EXPERIMENTAL
Intervention: Isometric resistance training (IRT) at 30% of maximum voluntary contraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isometric resistance training (IRT) at 5% of maximum voluntary contraction
Number of subjects: 40
Study: 24885942

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 3000 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 22273665

Group type: EXPERIMENTAL
Intervention: Severe PVD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing PVD severity
Number of subjects: 0
Study: 20176715

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Baseline RV peak systolic strain
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: RV peak systolic strain at 48 to 72 hours
Number of subjects: 62
Study: 19319752

Group type: EXPERIMENTAL
Intervention: Spinergy wheelchair wheels
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional steel-spoked wheelchair wheels
Number of subjects: 13
Study: 15857067

Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride-iontophoresis (NaF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aqueous solution of hydroxy-ethyl-methacrylate and glutaraldehyde (HEMA-G)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both agents (NaF and HEMA-G)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Teeth requiring repeat dosage
Number of subjects: 50
Study: 12769403

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 0
Study: 12091047

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no thrombolytic therapy)
Number of subjects: 0
Study: 9874451

Group type: EXPERIMENTAL
Intervention: EEP (etoposide 120 mg/m2, epirubicin 30 mg/m2, cisplatin 40 mg/m2 on Days 1 and 8)
Number of subjects: 131

Group type: COMPARATOR
Intervention: FEP (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cisplatin 80 mg/m2 on Day 1)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: EEP
Number of subjects: 131

Group type: COMPARATOR
Intervention: FEP
Number of subjects: 131
Study: 8594118

Group type: EXPERIMENTAL
Intervention: Refrigerant topical anesthetic
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo topical spray
Number of subjects: 90

Group type: COMPARATOR
Intervention: No-spray control
Number of subjects: 90
Study: 2087335

Group type: EXPERIMENTAL
Intervention: Ga-As laser applied to acupuncture points (LI 10, 11, 12, Lu 5, SJ 5)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study: 38680

Group type: EXPERIMENTAL
Intervention: 1.0 mg atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 mg hyoscine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 mg glycopyrronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no anticholinergic premedication)
Number of subjects: 0
Study: 6553250

Group type: EXPERIMENTAL
Intervention: IV tubing changed every 24 hours
Number of subjects: 130

Group type: COMPARATOR
Intervention: IV tubing changed every 48 hours
Number of subjects: 130

Group type: COMPARATOR
Intervention: IV tubing changed every 72 hours
Number of subjects: 130
Study: 29580249

Group type: EXPERIMENTAL
Intervention: Shared Decision-Making (SDM) implementation program
Number of subjects: 0
Study: 27459428

Group type: EXPERIMENTAL
Intervention: Theory-based tobacco education program
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard instruction
Number of subjects: 134
Study: 23794465

Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg·kg(‐1) daily for up to 10 days)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 217
Study: 22430522

Group type: EXPERIMENTAL
Intervention: Cutaneous traction
Number of subjects: 65

Group type: COMPARATOR
Intervention: Skeletal traction
Number of subjects: 65
Study: 20586601

Group type: COMPARATOR
Intervention: Standing at sea level for 3 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standing at high altitude (5050 m) for 3 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Initial responses to standing at HA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Middle cerebral artery blood velocity (MCAv) at 3 min
Number of subjects: 10
Study: 18236139

Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg) three times per day for 5 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15867662

Group type: EXPERIMENTAL
Intervention: Floseal
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 70
Study: 14658947

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 18

Group type: COMPARATOR
Intervention: Various NSAIDs (including aspirin and sulindac)
Number of subjects: 18
Study: 10783359

Group type: EXPERIMENTAL
Intervention: CDB-2914 (10 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CDB-2914 (50 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CDB-2914 (100 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CDB-2914 (all doses)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9254992

Group type: EXPERIMENTAL
Intervention: Oral hydration
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Furosemide diuresis
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 65
Study: 1387929

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 187

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 187
Study: 6696210

Group type: EXPERIMENTAL
Intervention: Ispaghula suspension (oral challenge)
Number of subjects: 6
Study: 31227014

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily for 90 days
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 189
Study: 28948979

Group type: EXPERIMENTAL
Intervention: LPS (2 ng/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 29
Study: 26944475

Group type: EXPERIMENTAL
Intervention: HOXA-positive early thymic precursor
Number of subjects: 209

Group type: COMPARATOR
Intervention: HOXA-negative early thymic precursor
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: HOXA-positive cases with chemoresistance
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: HOXA-positive cases with minimal residual disease positivity
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: HOXA positivity
Number of subjects: 209
Study: 24378958

Group type: EXPERIMENTAL
Intervention: 100 mg doxycycline daily for 4 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 22157087

Group type: EXPERIMENTAL
Intervention: Mustard preparation (20 g, 25 mg total ITC) daily for 4 days
Number of subjects: 14
Study: 20400377

Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% w/w capsaicin patch), applied for 60 minutes
Number of subjects: 0
Study: 18568273

Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP approximately T + hepatitis B vaccine at 0, 6, and 14 weeks
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP approximately T + hepatitis B vaccine at 6, 10, and 14 weeks
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP approximately T
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP approximately T + hepatitis B vaccine
Number of subjects: 424
Study: 16053121

Group type: EXPERIMENTAL
Intervention: Breath therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 36
Study: 12358164

Group type: EXPERIMENTAL
Intervention: Overdrive atrial pacing before cardioversion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stable atrial capture
Number of subjects: 15

Group type: COMPARATOR
Intervention: No atrial capture
Number of subjects: 15
Study: 10562843

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blinded control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informed consent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Professional equipoise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Utilitarian philosophy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Managed care
Number of subjects: 0
Study: 8983643

Group type: EXPERIMENTAL
Intervention: Epicutaneous (EP) test
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intradermic (ID) test
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of EP and ID tests
Number of subjects: 45
Study: 1856301

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Attention control intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 7109988

Group type: EXPERIMENTAL
Intervention: Remote mental healing treatment by healers
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (normal medical treatment)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Healers' treatment
Number of subjects: 96
Study: 27626240

Group type: EXPERIMENTAL
Intervention: Single layer unlocked suturing
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Single layer locked suturing
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Double layer suturing
Number of subjects: 435

Group type: COMPARATOR
Intervention: Double layer closure
Number of subjects: 435

Group type: COMPARATOR
Intervention: Single layer unlocked suture
Number of subjects: 435
Study: 27460638

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with anthracyclines
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy without anthracyclines
Number of subjects: 1066
Study: 23928155

Group type: EXPERIMENTAL
Intervention: Cortical screws
Number of subjects: 80

Group type: COMPARATOR
Intervention: Miniplates
Number of subjects: 80
Study: 23778382

Group type: EXPERIMENTAL
Intervention: 400 mg/day amisulpride plus 800 mg/day sulpiride
Number of subjects: 92

Group type: COMPARATOR
Intervention: 800 mg/day amisulpride
Number of subjects: 92
Study: 20573482

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All randomized participants
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Meta-regression
Number of subjects: 10
Study: 17981885

Group type: EXPERIMENTAL
Intervention: 0.55 g/kg/day protein diet
Number of subjects: 392

Group type: COMPARATOR
Intervention: 0.8 g/kg/day protein diet
Number of subjects: 392
Study: 15698702

Group type: EXPERIMENTAL
Intervention: Cooling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heating
Number of subjects: 0
Study: 12854480

Group type: EXPERIMENTAL
Intervention: Carbon-fiber resistive-heating blanket
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lower-body forced-air system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Circulating water mattress
Number of subjects: 24
Study: 10564629

Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Telephone plus letter
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: In-person plus letter
Number of subjects: 808

Group type: COMPARATOR
Intervention: Physician letter
Number of subjects: 808

Group type: COMPARATOR
Intervention: Telephone alone
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Telephone-plus-letter
Number of subjects: 808
Study: 8729588

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day combined with bezafibrate 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin 10 mg combined with cholestyramine 8 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with cholestyramine 8 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin 10 mg combined with cholestyramine 8 g/day after 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with cholestyramine 8 g/day after 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluvastatin 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Niacin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg combined with niacin (3 g/day)
Number of subjects: 0
Study: 1678271

Group type: EXPERIMENTAL
Intervention: 14 mg transdermal patch
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7 to 21 mg transdermal patches
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: transdermal patches
Number of subjects: 12
Study: 6137977

Group type: EXPERIMENTAL
Intervention: Vecuronium (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pancuronium bromide (group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium (group C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pancuronium bromide (group D)
Number of subjects: 50
Study: 30580464

Group type: EXPERIMENTAL
Intervention: Personalized melanoma genomic risk information
Number of subjects: 30
Study: 29873739

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25582578

Group type: EXPERIMENTAL
Intervention: Diosmectite group (diosmectite and mesalazine)
Number of subjects: 120
Study: 24223806

Group type: EXPERIMENTAL
Intervention: Web-based brief alcohol intervention
Number of subjects: 907

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 907
Study: 21999125

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20035586

Group type: EXPERIMENTAL
Intervention: Equasym XL/Metadate CD
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Concerta
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 184
Study: 17242633

Group type: COMPARATOR
Intervention: Calcium supplementation (group A, n = 22)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol at a dose of 50 mug/day and nomegestrol at a dose of 5 mg/day (group B, n = 22)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 14739793

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EACA and Aprotinin
Number of subjects: 36
Study: 11159619

Group type: EXPERIMENTAL
Intervention: Streptococcal spray
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 130
Study: 9627950

Group type: EXPERIMENTAL
Intervention: Oxaprozin for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diclofenac retard for 6 weeks
Number of subjects: 80
Study: 8682023

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 2146452

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 0
Study: 335912

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg orally twice daily for 1 week)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pilocarpine (2% eyedrops three times a day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol and Pilocarpine (combined treatment)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study: 31350269

Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg once daily
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg once daily
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 24841333

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of BP using the CNAP® Monitor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent oscillometric BP cuff
Number of subjects: 40